<SEC-DOCUMENT>0001193125-25-049944.txt : 20250307
<SEC-HEADER>0001193125-25-049944.hdr.sgml : 20250307
<ACCEPTANCE-DATETIME>20250307170104
ACCESSION NUMBER:		0001193125-25-049944
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250307
DATE AS OF CHANGE:		20250307

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intra-Cellular Therapies, Inc.
		CENTRAL INDEX KEY:			0001567514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				364742850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36274
		FILM NUMBER:		25721018

	BUSINESS ADDRESS:	
		STREET 1:		135 ROUTE 202/206
		STREET 2:		SUITE 6
		CITY:			BEDMINSTER
		STATE:			NJ
		ZIP:			07921
		BUSINESS PHONE:		(646) 440-9333

	MAIL ADDRESS:	
		STREET 1:		135 ROUTE 202/206
		STREET 2:		SUITE 6
		CITY:			BEDMINSTER
		STATE:			NJ
		ZIP:			07921

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oneida Resources Corp.
		DATE OF NAME CHANGE:	20130122

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>d866658ddfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<HTML><HEAD>
<TITLE>DFAN14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&#8195; ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&#9746; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Intra-Cellular Therapies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Johnson&nbsp;&amp; Johnson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is an email message from Jennifer Taubert and John Reed of Johnson&nbsp;&amp; Johnson to
Intra-Cellular Therapies, Inc. employees sent on March&nbsp;7, 2025. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>From: </B>Jennifer Taubert&nbsp;&amp; John Reed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>To: </B>All Intra-Cellular Therapies Employees </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date:</B>
March 7, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subject: </B>A Message from Jennifer Taubert&nbsp;&amp; John Reed at Johnson&nbsp;&amp; Johnson </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Intra-Cellular Therapies Colleagues,</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for hosting
us at last week&#146;s town hall meeting. We were thrilled to meet so many of you in person and others online. We appreciated your engagement, enthusiasm, and candor as we take this exciting first step in planning to unite our two companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commend you for the impressive success you have achieved as well as the strong culture you&#146;ve built, a culture that closely aligns with our own. As
Our Credo articulates, we share your dedication to putting the needs and well-being of the patients we serve first. We, too, welcome curiosity and celebrate science, built on a culture of integrity and respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future we are working towards will be transformative for our patients. Your outstanding scientific expertise and mission-focused team &#150; combined with
Johnson&nbsp;&amp; Johnson &#150; will allow us to advance novel treatments and provide new hope for even more patients living with neuropsychiatric and neurodegenerative disorders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shared previously, we are committed to transparency throughout this process and hope we addressed your initial questions at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you again for attending the town hall. We look forward to welcoming you to Johnson&nbsp;&amp; Johnson and achieving even greater things for patients
together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warm Regards,</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jennifer Taubert</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Worldwide Chairman, Innovative Medicine</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John Reed, M.D., Ph.D.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, R&amp;D,
Innovative Medicine</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADDITIONAL INFORMATION AND WHERE TO FIND IT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication may be deemed to be solicitation material in respect of the proposed acquisition of Intra-Cellular Therapies by Johnson&nbsp;&amp; Johnson.
In connection with the proposed transaction, on February&nbsp;18, 2025, Intra-Cellular Therapies filed a definitive proxy statement with the Securities and Exchange Commission (the &#147;SEC&#148;). Beginning on February&nbsp;18, 2025, the
definitive proxy statement and proxy card were mailed to Intra-Cellular Therapies&#146; stockholders of record as of February&nbsp;13, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVESTORS
AND STOCKHOLDERS OF INTRA-CELLULAR THERAPIES ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING INTRA-CELLULAR THERAPIES&#146; PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and stockholders of Intra-Cellular Therapies are or will be able to
obtain these materials (when they are available) free of charge at the SEC&#146;s website at www.sec.gov, or free of charge from Intra-Cellular Therapies&#146; website at www.intracellulartherapies.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PARTICIPANTS IN THE SOLICITATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp;
Johnson and Intra-Cellular Therapies and certain of their respective directors and executive officers, under SEC rules, may be deemed to be &#147;participants&#148; in the solicitation of proxies from stockholders of Intra-Cellular Therapies in
connection with the proposed transaction. Information about Johnson&nbsp;&amp; Johnson&#146;s directors and executive officers is available in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2023, which was filed with the SEC on February&nbsp;16, 2024, and Johnson&nbsp;&amp; Johnson&#146;s definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on
March&nbsp;13, 2024. Information about Intra-Cellular Therapies&#146; directors and executive officers is available in Intra-Cellular Therapies&#146; Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2023, which was filed with the SEC on February&nbsp;22, 2024, and Intra-Cellular Therapies&#146; definitive proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on April&nbsp;29, 2024. To the
extent holdings of Johnson&nbsp;&amp; Johnson&#146;s or Intra-Cellular Therapies&#146; securities by their respective directors or executive officers have changed since the amounts set forth in such 2024 proxy statements, such changes have been or
will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including the Form 3 filed by Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097291/xslF345X02/ownership.xml">
<U>August</U><U></U><U>&nbsp;14, 2024</U></A> and the Form 4s filed by: Sharon Mates on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
23, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
28, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
30, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/xslF345X05/ownership.xml"><U>December</U><U></U><U>&nbsp;
6, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013765/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Joel S. Marcus on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075079/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>,<A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077469/xslF345X05/ownership.xml"><U> June</U><U></U><U>&nbsp;
25, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025028030/xslF345X05/ownership.xml">February<U></U>&nbsp;
26, 2025</A>; Rory B. Riggs on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075081/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077468/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080986/xslF345X05/ownership.xml"><U>July</U><U></U><U>&nbsp;
2, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024111766/xslF345X05/ownership.xml"><U>October</U><U></U><U>&nbsp;
2, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024114785/xslF345X05/ownership.xml"><U>October</U><U></U><U>&nbsp;
15, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025001440/xslF345X05/ownership.xml"><U>January</U><U></U><U>&nbsp;
3, 2025</U></A>; Eduardo Rene Salas on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075082/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077470/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A>; Robert L. Van Nostrand on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075077/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024076380/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
21, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077472/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080987/xslF345X05/ownership.xml"><U>July</U><U></U><U>&nbsp;
2, 2024</U></A>; Michael Halstead on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024127275/xslF345X05/ownership.xml"><U>November</U><U></U><U>&nbsp;
14, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013763/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Mark Neumann on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
20, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013762/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Suresh K. Durgam on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013749/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; and Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097292/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
14, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013670/xslF345X05/ownership.xml">February<U></U>&nbsp;4, 2025</A>. Investors and stockholders of Intra-Cellular Therapies are or will be able to obtain these
documents free of charge from the SEC&#146;s website at www.sec.gov, from Johnson&nbsp;&amp; Johnson on Johnson&nbsp;&amp; Johnson&#146;s website at www.jnj.com, from Intra-Cellular Therapies on Intra-Cellular Therapies&#146; website at
www.intracellulartherapies.com. or on request from Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. Additional information concerning the interests of Intra-Cellular Therapies&#146; participants in the solicitation, which may, in some cases,
be different than those of Intra-Cellular Therapies&#146; stockholders generally, is included in Intra-Cellular Therapies&#146; definitive proxy statement relating to the proposed transaction, which was filed with the SEC on February&nbsp;18, 2025.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This communication contains &#147;forward-looking statements&#148; regarding the acquisition of Intra-Cellular
Therapies by Johnson&nbsp;&amp; Johnson. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown
risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. Risks and uncertainties include, but are not limited to: the risk that the
closing conditions for the acquisition will not be satisfied; uncertainty as to the percentage of Intra-Cellular Therapies stockholders that will vote to approve the proposed transaction at the Intra-Cellular Therapies stockholder meeting; the
possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to the businesses of Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies during the pendency of the transaction, such as
employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the
acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the
risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care
reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition, there will be risks and uncertainties related to the ability of the Johnson&nbsp;&amp; Johnson
family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of Intra-Cellular Therapies. A further list and description of these risks, uncertainties and other factors and the general
risks associated with the respective businesses of Johnson&nbsp;&amp; Johnson and Intra-Cellular Therapies can be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2024, filed with the SEC on February&nbsp;13, 2025, including in the sections captioned &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Johnson&nbsp;&amp;
Johnson&#146;s subsequent filings with the SEC and in Intra-Cellular Therapies&#146; Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on February&nbsp;21, 2025,
including in the sections captioned &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Intra-Cellular Therapies&#146; subsequent filings with the SEC. Copies of these filings, as well
as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.intracellulartherapies.com, or on request from Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neither Johnson&nbsp;&amp; Johnson nor Intra-Cellular Therapies undertakes to update any forward-looking
statement as a result of new information or future events or developments, except as required by law. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cautions Concerning Forward-Looking Statements </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains &#147;forward-looking statements&#148; regarding the acquisition of Intra-Cellular Therapies by Johnson&nbsp;&amp; Johnson. The
reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual
results could vary materially from the expectations and projections of Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the acquisition will not
be satisfied; uncertainty as to the percentage of Intra-Cellular Therapies stockholders that will vote to approve the proposed transaction at the Intra-Cellular Therapies stockholder meeting; the possibility that the transaction will not be
completed in the expected timeframe or at all; potential adverse effects to the businesses of Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies during the pendency of the transaction, such as employee departures or distraction of management
from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may
take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing
difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations;
competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government
action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there will be risks and uncertainties related to the ability of the Johnson&nbsp;&amp; Johnson family of companies to successfully integrate the
programs, products, technologies and employees/operations and clinical work of Intra-Cellular Therapies. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses
of Johnson&nbsp;&amp; Johnson and Intra-Cellular Therapies can be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on
February&nbsp;13, 2025, including in the sections captioned &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Johnson&nbsp;&amp; Johnson&#146;s subsequent filings with the SEC and in
Intra-Cellular Therapies&#146; Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on February&nbsp;21, 2025, including in the sections captioned &#147;Cautionary
Statement Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Intra-Cellular Therapies&#146; subsequent filings with the SEC. Copies of these filings, as well as subsequent filings, are available online at
<U>www.sec.gov</U>, <U>www.jnj.com</U>, <U>www.intracellulartherapies.com</U>, or on request from Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Johnson&nbsp;&amp; Johnson nor Intra-Cellular Therapies undertakes to update any forward-looking statement as a result of new information or future
events or developments, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Participants in the Solicitation </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson and Intra-Cellular Therapies and certain of their respective directors and executive officers, under SEC rules, may be deemed to be
&#147;participants&#148; in the solicitation of proxies from stockholders of Intra-Cellular Therapies in connection with the proposed transaction. Information about Johnson&nbsp;&amp; Johnson&#146;s directors and executive officers is available in
Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, which was filed with the SEC on February&nbsp;16, 2024, and Johnson&nbsp;&amp; Johnson&#146;s definitive
proxy statement for its 2024 annual meeting of stockholders, which was filed with the SEC on March&nbsp;13, 2024. Information about Intra-Cellular Therapies&#146; directors and executive officers is available in Intra-Cellular Therapies&#146; Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, which was filed with the SEC on February&nbsp;22, 2024, and Intra-Cellular Therapies&#146; definitive proxy statement for its 2024 annual meeting
of stockholders, which was filed with the SEC on April&nbsp;29, 2024. To the extent holdings of Johnson&nbsp;&amp; Johnson&#146;s or Intra-Cellular Therapies&#146; securities by their respective directors or executive officers have changed since the
amounts set forth in such 2024 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including the Form 3 filed by
Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097291/xslF345X02/ownership.xml"><U>August</U><U></U><U>&nbsp;
14, 2024</U></A> and the Form 4s filed by: Sharon Mates on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
23, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
28, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
30, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/xslF345X05/ownership.xml"><U>December</U><U></U><U>&nbsp;
6, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013765/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Joel S. Marcus on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075079/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>,<A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077469/xslF345X05/ownership.xml"><U> June</U><U></U><U>&nbsp;
25, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025028030/xslF345X05/ownership.xml">February<U></U>&nbsp;
26, 2025</A>; Rory B. Riggs on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075081/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077468/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080986/xslF345X05/ownership.xml"><U>July</U><U></U><U>&nbsp;
2, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024111766/xslF345X05/ownership.xml"><U>October</U><U></U><U>&nbsp;
2, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024114785/xslF345X05/ownership.xml"><U>October</U><U></U><U>&nbsp;
15, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025001440/xslF345X05/ownership.xml"><U>January</U><U></U><U>&nbsp;
3, 2025</U></A>; Eduardo Rene Salas on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075082/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077470/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A>; Robert L. Van Nostrand on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024075077/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
18, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024076380/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
21, 2024</U></A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024077472/xslF345X05/ownership.xml"><U>June</U><U></U><U>&nbsp;
25, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024080987/xslF345X05/ownership.xml">July&nbsp;
2, 2024</A>; Michael Halstead on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024127275/xslF345X05/ownership.xml"><U>November</U><U></U><U>&nbsp;
14, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013763/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Mark Neumann on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024099258/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
20, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013762/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; Suresh K. Durgam on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013749/xslF345X05/ownership.xml">February<U></U>&nbsp;
4, 2025</A>; and Sanjeev Narula on <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017024097292/xslF345X05/ownership.xml"><U>August</U><U></U><U>&nbsp;
14, 2024</U></A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1567514/000095017025013670/xslF345X05/ownership.xml">February<U></U>&nbsp;4, 2025</A>. Investors and stockholders of Intra-Cellular Therapies are or will be able to obtain these
documents free of charge from the SEC&#146;s website at www.sec.gov, from Johnson&nbsp;&amp; Johnson on Johnson&nbsp;&amp; Johnson&#146;s website at www.jnj.com, from Intra-Cellular Therapies on Intra-Cellular Therapies&#146; website at
www.intracellulartherapies.com. or on request from Johnson&nbsp;&amp; Johnson or Intra-Cellular Therapies. Additional information concerning the interests of Intra-Cellular Therapies&#146; participants in the solicitation, which may, in some cases,
be different than those of Intra-Cellular Therapies&#146; stockholders generally, is included in Intra-Cellular Therapies&#146; definitive proxy statement relating to the proposed transaction, which was filed with the SEC on February&nbsp;18, 2025.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional Information and Where to Find It </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
communication may be deemed to be solicitation material in respect of the proposed acquisition of Intra-Cellular Therapies by Johnson&nbsp;&amp; Johnson. In connection with the proposed transaction, on February&nbsp;18, 2025, Intra-Cellular
Therapies filed a definitive proxy statement with the Securities and Exchange Commission (the &#147;SEC&#148;). Beginning on February&nbsp;18, 2025, the definitive proxy statement and proxy card were mailed to Intra-Cellular Therapies&#146;
stockholders of record as of February&nbsp;13, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INVESTORS AND STOCKHOLDERS OF INTRA-CELLULAR THERAPIES ARE URGED TO READ ALL RELEVANT DOCUMENTS
FILED WITH THE SEC, INCLUDING INTRA-CELLULAR THERAPIES&#146; PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and stockholders of Intra-Cellular Therapies are or will be able to obtain these materials (when they are available) free of charge at the
SEC&#146;s website at <U>www.sec.gov</U>, or free of charge from Intra-Cellular Therapies&#146; website at <U>www.intracellulartherapies.com</U>. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
